For Great Britain healthcare professionals only
Hosting partners
GP Notebook
diabetes on the net

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content, logistics and selection of speakers. OmniaMed Communications has provided editorial, marketing and logistical support. © 2023 Bayer plc

Click here for Great Britain Prescribing Information for Kerendia▼ (finerenone). Adverse Event Reporting details can be found at the bottom of the page

CKD and T2D:
Developments in the management of diabetic kidney disease (DKD)
Resource hub

Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can access a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.

Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.

NICE TA877 guidance

Finerenone for treating chronic kidney disease in type 2 diabetes1

Technology appraisal guidance [TA877]
Published: 23 March 2023

Recommendation

1.1 Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if:

  • it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
    • angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
    • sodium–glucose co-transporter-2 (SGLT2) inhibitors and
  • the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.
© NICE [2023] TA877. Available from https://www.nice.org.uk/guidance/. All rights reserved. Subject to Notice of Rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

In the FIDELIO-DKD phase 3 randomised, double-blind, placebo-controlled, multicentre clinical trial of 5734 adult patients with type 2 diabetes and chronic kidney disease who were randomised 1:1 to receive either oral finerenone or placebo, at baseline approximately 124 (4.4%) patients in the finerenone arm and 135 (4.8%) in the placebo arm were on SGLT2 inhibitors.2

Although recommendations for the use of an SGLT2 inhibitor in patients with chronic kidney disease and type 2 diabetes were introduced after the initiation of FIDELIO-DKD in 2015, a limited number of patients received concomitant SGLT2 inhibitor treatment during the FIDELIO-DKD trial.3

SMC ADVICE: following a full submission4

Finerenone (Kerendia®) is accepted for use within NHS Scotland.

Indication under review: for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

In a randomised, double-blind, phase III study, the addition of finerenone to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker reduced the risk of the primary composite renal outcome comprising kidney failure, a sustained decrease in estimated glomerular filtration rate of ≥40% or death from renal causes compared with placebo.

The total incidence of treatment-emergent adverse events was similar between the two groups; 87.3% (n=2468/2827) of Kerendia patients vs 87.5% (n=2478/2831) receiving placebo.2 Hyperkalaemia was more common in patients receiving Kerendia than placebo; 18.3% (n=516/2827) vs 9.0% (n=255/2831),  respectively.2 Serious events of hyperkalaemia were reported in 1.6% (n=44/2827) of Kerendia patients vs  0.4% (n=12/2831) receiving placebo.2 For more information visit https://go.bayer.com/SMCKerendia or email [email protected]

References:

  1. NICE (2023). Finerenone for treating chronic kidney disease in people with type 2 diabetes [TA877] Technology Appraisal Guidance. Available at: www.nice.org.uk/guidance/ta877 (accessed April 2023)
  2. Bakris GL et al. N Engl J Med 2020;282:2219–29
  3. Rossing P et al. Kidney Int Rep 2021;7:36–45
  4. Scottish Medicines Consortium (2022). Finerenone 10mg and 20mg film-coated tablets (Kerendia®) SMC2486. Available at: https://www.scottishmedicines.org.uk/media/7206/finerenone-kerendia-final-oct-2022docxfor-website.pdf (accessed April 2023)

Stay connected with Bayer electronic communications about Bayer’s products, services and events, some of which may be promotional in nature, by registering at pro.bayer.co.uk

Alternatively, open your phone camera application, hold it over the QR code and tap the link that appears.

Click here for Great Britain Prescribing Information for Kerendia▼ (finerenone).
Reporting adverse events and quality complaints ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: [email protected] Further information is available on the “contact” tab at www.bayer.co.uk.
PP-KER-GB-0395 | April 2023

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content, logistics and selection of speakers.
OmniaMed Communications has provided editorial, marketing and logistical support.
© 2023 Bayer plc

For Great Britain healthcare professionals only
GP Notebook

Are you a Great Britain healthcare professional?

The information is intended for Great Britain healthcare professionals only.
Please confirm below.

I confirm I am a Great Britain healthcare professional.
I confirm I am a Northern Ireland healthcare professional.
I am not a Great Britain or Northern Ireland healthcare professional.
GP Notebook

You are leaving GP Notebook

GP Notebook is not responsible for content hosted on third party websites.

Continue
Close
GP Notebook

You are leaving GP Notebook

GP Notebook is not responsible for content hosted on third party websites

You will be redirected to:
https://www.scottishmedicines.org.uk/medicines-advice/finerenone-kerendia-full-smc2486/

Continue
Close

You are leaving diabetesonthenet.com

We are not responsible for content hosted on third party websites.
You will be directed to: https://yellowcard.mhra.gov.uk

Go back
Continue
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel